Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Within each content area, there are one or more tutorials. Each tutorial consists of lessons. Each lesson should be a page detailing the concept being taught, along with sample code. Lesson and page ...